Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
Mainz Biomed (NASDAQ:MYNZ), a molecular genetics diagnostic company focused on early cancer detection, has announced the pricing of a $3.0 million follow-on offering. The offering consists of 2,222,222 units priced at $1.35 per unit, with each unit including one ordinary share (or pre-funded warrant) and one Series A warrant.
The Series A warrants will be immediately exercisable at $1.35 per share with a five-year expiration term. Maxim Group LLC serves as the sole placement agent, with the offering expected to close around August 5, 2025, subject to customary conditions.
Mainz Biomed (NASDAQ:MYNZ), un'azienda di diagnostica genetica molecolare specializzata nella rilevazione precoce del cancro, ha annunciato il prezzo di un'offerta secondaria da 3,0 milioni di dollari. L'offerta comprende 2.222.222 unit脿 al prezzo di 1,35 dollari per unit脿, con ogni unit脿 che include una azione ordinaria (o un warrant pre-finanziato) e un warrant di Serie A.
I warrant di Serie A saranno immediatamente esercitabili a 1,35 dollari per azione con una scadenza di cinque anni. Maxim Group LLC agisce come unico agente di collocamento, e la chiusura dell'offerta 猫 prevista intorno al 5 agosto 2025, soggetta a condizioni consuete.
Mainz Biomed (NASDAQ:MYNZ), una empresa de diagn贸stico gen茅tico molecular enfocada en la detecci贸n temprana del c谩ncer, ha anunciado el precio de una oferta secundaria de 3,0 millones de d贸lares. La oferta consta de 2.222.222 unidades a un precio de 1,35 d贸lares por unidad, cada unidad incluye una acci贸n ordinaria (o un warrant prefinanciado) y un warrant Serie A.
Los warrants Serie A podr谩n ejercerse inmediatamente a 1,35 d贸lares por acci贸n con un plazo de vencimiento de cinco a帽os. Maxim Group LLC act煤a como agente colocador exclusivo, y se espera que la oferta cierre alrededor del 5 de agosto de 2025, sujeta a condiciones habituales.
Mainz Biomed (NASDAQ:MYNZ)電� 臁瓣赴 鞎� 歆勲嫧鞐� 欷戩爯鞚� 霊� 攵勳瀽 鞙犾爠頃� 歆勲嫧 須岇偓搿�, 300毵� 雼煬 攴滊鞚� 頉勳啀 瓿惦 臧�瓴╈潉 氚滍憸頄堨姷雼堧嫟. 鞚措矆 瓿惦電� 2,222,222 雼渼搿� 雼渼雼� 1.35雼煬鞐� 毂呾爼霅橃棃鞙茧┌, 臧� 雼渼鞐愲姅 氤错喌欤�(霕愲姅 靹犽Г靾橁秾) 1欤检檧 鞁滊Μ歃� A 鞗岆煱韸� 1欤缄皜 韽暔霅橃柎 鞛堨姷雼堧嫟.
鞁滊Μ歃� A 鞗岆煱韸鸽姅 歃夓嫓 頄夓偓 臧�電ロ晿氅�, 頄夓偓臧�瓴╈潃 欤茧嫻 1.35雼煬鞚搓碃 毵岆 旮瓣皠鞚� 5雲勳瀰雼堧嫟. Maxim Group LLC臧� 雼弲 氚办爼 雽�頄夓偓搿� 頇滊彊頃橂┌, 鞚措矆 瓿惦電� 鞚茧皹鞝侅澑 臁瓣贝鞚� 於╈”頃橂姅 瓴冹潉 鞝勳牅搿� 2025雲� 8鞗� 5鞚缄步 毵堦皭霅� 鞓堨爼鞛呺媹雼�.
Mainz Biomed (NASDAQ:MYNZ), une soci茅t茅 de diagnostic g茅n茅tique mol茅culaire sp茅cialis茅e dans la d茅tection pr茅coce du cancer, a annonc茅 le prix d'une offre secondaire de 3,0 millions de dollars. L'offre comprend 2 222 222 unit茅s au prix de 1,35 dollar par unit茅, chaque unit茅 incluant une action ordinaire (ou un bon de souscription pr茅financ茅) et un bon de souscription de s茅rie A.
Les bons de souscription de s茅rie A seront imm茅diatement exer莽ables au prix de 1,35 dollar par action avec une 茅ch茅ance de cinq ans. Maxim Group LLC agit en tant qu'agent unique de placement, l'offre devant se cl么turer aux alentours du 5 ao没t 2025, sous r茅serve des conditions habituelles.
Mainz Biomed (NASDAQ:MYNZ), ein molekulargenetisches Diagnostikunternehmen mit Fokus auf die Fr眉herkennung von Krebs, hat die Preisfestsetzung f眉r ein 3,0 Millionen US-Dollar Folgeangebot bekanntgegeben. Das Angebot umfasst 2.222.222 Einheiten zu einem Preis von 1,35 US-Dollar pro Einheit, wobei jede Einheit eine Stammaktie (oder einen vorausfinanzierten Warrant) und einen Serie A Warrant enth盲lt.
Die Serie A Warrants sind sofort aus眉bbar zum Preis von 1,35 US-Dollar pro Aktie mit einer Laufzeit von f眉nf Jahren. Maxim Group LLC fungiert als alleiniger Platzierungsagent, und der Abschluss des Angebots wird voraussichtlich um den 5. August 2025 erfolgen, vorbehaltlich 眉blicher Bedingungen.
- Warrants provide potential for additional future funding through exercise
- Successful registration and SEC approval of Form F-1
- Small offering size of only $3.0 million indicates limited funding raised
- Potential dilution for existing shareholders
- Low unit pricing at $1.35 may indicate weak market conditions
Insights
Mainz Biomed's $3M offering dilutes shareholders while providing minimal runway extension, suggesting urgent capital needs.
Mainz Biomed's announcement of a
The warrant exercise price of
This financing follows a clear pattern in the micro-cap biotech sector where companies facing cash constraints must accept increasingly dilutive terms. For diagnostic companies with high development and commercialization costs,
BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ)聽(鈥淢ainz Biomed鈥� or the 鈥淐ompany鈥�), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 2,222,222 units, with each unit consisting of one ordinary share (or pre-funded warrant in lieu thereof) and one Series A warrant to purchase one and one half ordinary shares for gross proceeds of approximately
Maxim Group LLC is acting as the sole placement agent for the offering. The offering is expected to close on or about August 5, 2025, subject to customary closing conditions.
The newly issued securities described above are being offered pursuant to a registration statement on Form F-1, as amended (File No. 333-289095) (the 鈥淩egistration Statement鈥�), which was declared effective by the Securities and Exchange Commission (the 鈥淪EC鈥�) on August 4, 2025. The offering is being made only by means of a prospectus which is a part of the Registration Statement. A final prospectus relating to the offering will be filed with the SEC. Copies of the final prospectus relating to this offering may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Please visit Mainz Biomed鈥檚 official website for investors at mainzbiomed.com/investors/ for more information
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company鈥檚 flagship product is ColoAlert庐, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert庐 is marketed across Europe. The Company is currently running a clinical study to prepare for its pivotal FDA clinical study and US regulatory approval. Mainz Biomed鈥檚 product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com.
For media inquiries
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
[email protected]
For investor inquiries, please contact [email protected]
Forward-Looking Statements
Certain statements made in this press release are 鈥渇orward-looking statements鈥� within the meaning of the 鈥渟afe harbor鈥� provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as 鈥渁nticipate鈥�, 鈥渂elieve鈥�, 鈥渆xpect鈥�, 鈥渆stimate鈥�, 鈥減lan鈥�, 鈥渙utlook鈥�, and 鈥減roject鈥� and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company鈥檚 expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the 鈥淪EC鈥�) by the Company. Additional information concerning these and other factors that may impact the Company鈥檚 expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025. The Company鈥檚 SEC filings are available publicly on the SEC鈥檚 website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
FAQ
What is the size and price of Mainz Biomed's (MYNZ) follow-on offering in August 2025?
What does each unit in MYNZ's offering include?
What are the terms of MYNZ's Series A warrants?
When is MYNZ's follow-on offering expected to close?
Who is the placement agent for Mainz Biomed's offering?
